Search results
Results from the WOW.Com Content Network
The following are medications commonly prescribed cardiac pharmaceutical agents. The specificity of the following medications is highly variable, and often are not particularly specific to a given class. As such, they are listed as are commonly accepted.
Cardiac stress testing is used to determine to assess cardiac function and to disclose evidence of exertion-related cardiac hypoxia. Radionuclide testing using thallium or technetium can be used to demonstrate areas of perfusion abnormalities. With a maximal stress test the level of exercise is increased until the person's heart rate will not ...
In hematology, effective circulating volume (ECV) is the volume of arterial blood effectively perfusing tissue. [ 1 ] [ 2 ] ECV is a dynamic quantity and not a measurable, distinct compartment. [ 1 ] This concept is useful for discussion of cardiovascular and renal physiology.
Cardiovascular agents are drugs used to treat diseases associated with the heart or blood vessels. These medications are available for purchase only with a physician’s prescription . They include, but are not limited to, drugs that target hypertension ( antihypertensives ), hyperlipidemia ( antihyperlipidemics ) and blood clotting (blood ...
Other tests may include an electrocardiogram (ECG) to measure the heart's electrical activity, and blood tests to check for elevated levels of certain enzymes that may indicate heart damage. [8] If the diagnosis is confirmed, treatment typically involves stopping alcohol consumption and managing heart failure symptoms through medications ...
Coronary steal is also the mechanism in most drug-based cardiac stress tests; When a patient is incapable of doing physical activity they are given a vasodilator that produces a "cardiac steal syndrome" as a diagnostic procedure. The test result is positive if the patient's symptoms reappear or if ECG alterations are seen. [citation needed]
The FDA approved the CardiAssist ECP system for the treatment of angina, acute myocardial infarction and cardiogenic shock under a 510(k) submission in 1980 [1] [failed verification] Since then, additional ECP devices have been cleared by the FDA for use in treating stable or unstable angina pectoris, acute myocardial infarction, cardiogenic shock, and congestive heart failure.
Studies have shown that medications such as Digoxin, beta blockers, calcium channel blockers, and anti-arrhythmic medications can slow down heart conduction in patients with pre-existing cardiac conditions. [8] Since other cardiac conditions can be associated with Lev's disease, it is important to promote a heart healthy lifestyle. [24]